The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing.
Target repurposing utilizes knowledge of "druggable" targets obtained in one organism and exploits this information to pursue new potential drug targets in other organisms. Here we describe such studies to evaluate whether inhibitors targeting the kinase domain of the mammalian Target of R...
Saved in:
Main Authors: | Rosario Diaz-Gonzalez (Author), F Matthew Kuhlmann (Author), Cristina Galan-Rodriguez (Author), Luciana Madeira da Silva (Author), Manuel Saldivia (Author), Caitlin E Karver (Author), Ana Rodriguez (Author), Stephen M Beverley (Author), Miguel Navarro (Author), Michael P Pollastri (Author) |
---|---|
Format: | Book |
Published: |
Public Library of Science (PLoS),
2011-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bioactive PI3-kinase/Akt/mTOR Inhibitors in Targeted Lung Cancer Therapy
by: Somayyeh Ghareghomi, et al.
Published: (2023) -
Targeting PI3K/mTOR signaling in cancer
by: Alexandre Arcaro
Published: (2014) -
Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus
by: Micol Silic-Benussi, et al.
Published: (2023) -
Repurposing the Trypanosomatidic GSK Kinetobox for the Inhibition of Parasitic Pteridine and Dihydrofolate Reductases
by: Matteo Santucci, et al.
Published: (2021) -
Anilinoquinoline based inhibitors of trypanosomatid proliferation.
by: Lori Ferrins, et al.
Published: (2018)